{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:46:43Z","timestamp":1782996403622,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Doravirine (DOR)-containing antiretroviral therapy (ART) has been recommended as first-line ART by China treatment guidelines since 2021. However, Real-world studies on DOR in China are scarce. We evaluated the real-world effectiveness of DOR-containing ART in Chinese people with HIV-1 (PWH), including treatment-na\u00efve people regardless of viral load (VL) at baseline and treatment-experienced people regardless if they were virologic suppression (VS) or not.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective, multicenter, observational study using medical chart review in seven hospitals, covering top-tier infectious disease hospitals across regions in China. All the participants who initiated DOR-containing ART during August 2021 and September 2023 were included and followed until September 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At baseline, higher proportions of the 352 participants were male (84.9%), from west region (78.7%), and mean age was 40.0 years. Of the 271 participants with available VL data to confirm the achievement of VS at week 48\u2009\u00b1\u20098 (271\/352), 22.1% were treatment-na\u00efve and 77.9% had prior antiretroviral experience. The adherence rate of DOR in the regimen or DOR\/3TC\/TDF single tablet was \u2265\u200980% in 91.5% of participants. Overall, DOR-containing ART achieved a VS rate of 93.7% (95% confidence interval: 90.8%, 96.6%), with rates of 90.0% and 94.8% observed in treatment-na\u00efve and treatment-experienced participants, respectively. Notably, among all six treatment-experienced people who were unsuppressed at baseline, 100% of participants were suppressed at week 48\u2009\u00b1\u20098. DOR-containing ART appeared to be well tolerated among Chinese PWH, with an adverse event profile consistent with that described in product label.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>DOR-containing ART is an effective treatment for Chinese PWH in real-world settings, regardless of their VLs and treatment experience at baseline.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>EUPAS (registration number: EUPAS103993), registered on [2023-03-23]; NMPA (registration number: CTR20231040), registered on [2023-04-10].<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-026-13533-x","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:24:40Z","timestamp":1781108680000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world effectiveness of doravirine-containing antiretroviral therapy in Chinese adults living with HIV-1: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hai","family":"Long","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinping","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghua","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renfang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Peebles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"issue":"03","key":"13533_CR1","first-page":"225","volume":"31","author":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention","year":"2025","unstructured":"National Center for AIDS\/STD Control and Prevention, Chinese Center for Disease Control and Prevention. National AIDS and sexually transmitted disease epidemic situation in December 2024. Chin J AIDS STD. 2025;31(03):225.","journal-title":"Chin J AIDS STD"},{"issue":"6","key":"13533_CR2","first-page":"1261","volume":"15","author":"Acquired Immunodeficiency Syndrome Professional Group of Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention","year":"2024","unstructured":"Acquired Immunodeficiency Syndrome Professional Group of Society of Infectious Diseases, Chinese Medical Association, Chinese Center for Disease Control and Prevention. Chinese Guideline for Diagnosis and Treatment of Human Immunodeficiency Virus Infection\/Acquired Immunodeficiency Syndrome (2024 Edition). Med J Peking Union Med Coll Hosp. 2024;15(6):1261\u201388.","journal-title":"Med J Peking Union Med Coll Hosp"},{"issue":"4","key":"13533_CR3","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1128\/AAC.02650-15","volume":"60","author":"M Feng","year":"2016","unstructured":"Feng M, Sachs NA, Xu M, Grobler J, Blair W, Hazuda DJ, et al. Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations. Antimicrob Agents Chemother. 2016;60(4):2241\u20137.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"13533_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/COH.0000000000000709","volume":"17","author":"AJ Stockdale","year":"2022","unstructured":"Stockdale AJ, Khoo S. Doravirine: its role in HIV treatment. Curr Opin HIV AIDS. 2022;17(1):4\u201314.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"13533_CR5","doi-asserted-by":"publisher","first-page":"e211","DOI":"10.1016\/S2352-3018(18)30021-3","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina JM, Squires K, Sax PE, Cahn P, Lombaard J, DeJesus E, et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211\u201320.","journal-title":"Lancet HIV"},{"issue":"4","key":"13533_CR6","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1093\/cid\/ciy540","volume":"68","author":"C Orkin","year":"2019","unstructured":"Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, et al. Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz\/Emtricitabine\/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2019;68(4):535\u201344.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"13533_CR7","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/QAI.0000000000002056","volume":"81","author":"M Johnson","year":"2019","unstructured":"Johnson M, Kumar P, Molina JM, Rizzardini G, Cahn P, Bickel M, et al. Switching to Doravirine\/Lamivudine\/Tenofovir Disoproxil Fumarate (DOR\/3TC\/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. J Acquir Immune Defic Syndr. 2019;81(4):463\u201372.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"13533_CR8","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1089\/aid.2022.0058","volume":"38","author":"M Garcia","year":"2022","unstructured":"Garcia M, Martellosio JP, Giraud V, B\u00e9raud G, Catroux M, Roblot F, Le Moal G. Efficacy and Safety of Doravirine-Based Regimens in Real Life: A Prospective Monocentric French Study. AIDS Res Hum Retroviruses. 2022;38(10):779\u201381.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"12","key":"13533_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1177\/09564624221116533","volume":"33","author":"R Denyer","year":"2022","unstructured":"Denyer R, Zemskova J, Benator DA. HIV treatment with dolutegravir and doravirine: rationale for selection and clinical outcomes in a highly treatment experienced population. Int J STD AIDS. 2022;33(12):1073\u20137.","journal-title":"Int J STD AIDS"},{"issue":"14","key":"13533_CR10","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1177\/09564624231195084","volume":"34","author":"L Calza","year":"2023","unstructured":"Calza L, Colangeli V, Pensalfine G, Appolloni L, Vitale S, Bon I, Viale P. Doravirine\/lamivudine\/tenofovir disoproxil fumarate in virologically suppressed people living with HIV: A real-life experience. Int J STD AIDS. 2023;34(14):1018\u201323.","journal-title":"Int J STD AIDS"},{"issue":"8","key":"13533_CR11","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1093\/jac\/dkad185","volume":"78","author":"P Perfezou","year":"2023","unstructured":"Perfezou P, Hall N, Duthe J-C, Abdi B, Seang S, Arvieux C, et al. Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study. J Antimicrob Chemother. 2023;78(8):1929\u201333.","journal-title":"J Antimicrob Chemother"},{"issue":"9","key":"13533_CR12","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(24)00150-4","volume":"11","author":"PGA Oomen","year":"2024","unstructured":"Oomen PGA, Wit F, Brinkman K, Vrouenraets SME, Mudrikova T, van Welzen BJ, van der Valk M. Real-world effectiveness and tolerability of switching to doravirine-based antiretroviral therapy in people with HIV: a nationwide, matched, prospective cohort study. Lancet HIV. 2024;11(9):e576\u201385.","journal-title":"Lancet HIV"},{"issue":"30","key":"13533_CR13","doi-asserted-by":"publisher","first-page":"e29855","DOI":"10.1097\/MD.0000000000029855","volume":"101","author":"M Mazzitelli","year":"2022","unstructured":"Mazzitelli M, Antoni MD, Castelli F, Ripamonti D, Zuglian G, Lapadula G, et al. Real-life use of Doravirine in treatment-experienced people living with HIV: A multicenter Italian study. Med (Baltim). 2022;101(30):e29855.","journal-title":"Med (Baltim)"},{"issue":"52","key":"13533_CR14","doi-asserted-by":"publisher","first-page":"e28488","DOI":"10.1097\/MD.0000000000028488","volume":"100","author":"M Mazzitelli","year":"2021","unstructured":"Mazzitelli M, Sasset L, Leoni D, Putaggio C, Cattelan AM. Real life use of dolutegravir doravirine dual regimen in experienced elderly PLWH with multiple comorbidities and on polypharmacy: A retrospective analysis. Med (Baltim). 2021;100(52):e28488.","journal-title":"Med (Baltim)"},{"issue":"8","key":"13533_CR15","doi-asserted-by":"publisher","first-page":"e0065424","DOI":"10.1128\/spectrum.00654-24","volume":"12","author":"M Mej\u00edas-Trueba","year":"2024","unstructured":"Mej\u00edas-Trueba M, Gutierrez-Valencia A, Llaves-Flores S, Roca-Oporto C, Herrero M, de la Sotomayor C, et al. Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life. Microbiol Spectr. 2024;12(8):e0065424.","journal-title":"Microbiol Spectr"},{"issue":"7","key":"13533_CR16","doi-asserted-by":"publisher","first-page":"104736","DOI":"10.1016\/j.idnow.2023.104736","volume":"53","author":"R Palich","year":"2023","unstructured":"Palich R, Saliba S, Landowski S, Abdi B, Valantin MA, Mahrez R, et al. Intermittent doravirine\/lamivudine\/tenofovir disoproxil fumarate (DOR\/3TC\/TDF) maintains a high level of viral suppression in virologically suppressed people living with HIV. Infect Dis Now. 2023;53(7):104736.","journal-title":"Infect Dis Now"},{"issue":"4","key":"13533_CR17","doi-asserted-by":"publisher","first-page":"e0081524","DOI":"10.1128\/aac.00815-24","volume":"69","author":"A Lazzaro","year":"2025","unstructured":"Lazzaro A, Recchia GE, Alessi F, Santinelli L, Battistini L, Morcos J, et al. Efficacy, safety, and anti-inflammatory properties of the switch to a doravirine-based regimen among antiretroviral-experienced elderly people living with HIV-1: the DORAGE cohort. Antimicrob Agents Chemother. 2025;69(4):e0081524.","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"13533_CR18","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1111\/hiv.70061","volume":"26","author":"C Wyen","year":"2025","unstructured":"Wyen C, Sabranski M, Jonsson-Oldenb\u00fcttel C, Bogner J, Knechten H, Esser S, et al. Effectiveness of switching to doravirine-based antiretroviral therapy: A real-world study in Germany. HIV Med. 2025;26(8):1289\u201399.","journal-title":"HIV Med"},{"issue":"12","key":"13533_CR19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.3390\/ph17121706","volume":"17","author":"S Cicalini","year":"2024","unstructured":"Cicalini S, Lanini S, Gagliardini R, Bellagamba R, Vergori A, Mastrorosa I, et al. Effectiveness and Tolerability of DOR\/3TC\/TDF in Experienced People with HIV Switching from RPV\/FTC\/TDF: A Retrospective, Single Center Cohort Study. Pharmaceuticals (Basel). 2024;17(12):1706.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"13533_CR20","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/QAI.0000000000003248","volume":"94","author":"M Poliseno","year":"2023","unstructured":"Poliseno M, Mazzitelli M, Narducci A, Ferrara SM, Resnati C, Gervasoni C, et al. Doravirine Plus Integrase Strand Transfer Inhibitors as a 2-Drug Treatment-Switch Strategy in People Living with HIV: The Real-Life DORINI Multicentric Cohort Study. J Acquir Immune Defic Syndr. 2023;94(3):235\u201343.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"13533_CR21","doi-asserted-by":"publisher","first-page":"1575411","DOI":"10.3389\/fmed.2025.1575411","volume":"12","author":"A Li","year":"2025","unstructured":"Li A, Liu L, Zhang H, Wang X, Li Z, Liu A, et al. Efficacy and safety of doravirine\/lamivudine\/tenofovir disoproxil fumarate in HIV treatment: a real-world single-center study in China. Front Med (Lausanne). 2025;12:1575411.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"13533_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1177\/09564624231215977","volume":"35","author":"C O\u2019Halloran","year":"2024","unstructured":"O\u2019Halloran C, Gilleece Y, Leung S, Canuto V, McAlpine C, Ross S, et al. Real world utilisation of doravirine among people living with human immunodeficiency virus in England (DRIVE-REAL). Int J STD AIDS. 2024;35(3):206\u201316.","journal-title":"Int J STD AIDS"},{"issue":"8","key":"13533_CR23","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1093\/jac\/dkae194","volume":"79","author":"C Soulie","year":"2024","unstructured":"Soulie C, Balde A, Fofana D, Charpentier C, Bonnafous P, Sourice J, et al. DORAVIR: a French national survey of people with HIV-1 treated with an antiretroviral regimen including doravirine. J Antimicrob Chemother. 2024;79(8):1974\u201384.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"13533_CR24","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1097\/QAD.0000000000004151","volume":"39","author":"A Rami","year":"2025","unstructured":"Rami A, Pozniak AL, Assoumou L, Movahedi R, Lacombe K, Raffi F, et al. Use of doravirine-based regimens in clinical practice in Europe. Aids. 2025;39(8):975\u201385.","journal-title":"Aids"},{"issue":"6","key":"13533_CR25","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/QAD.0000000000001408","volume":"31","author":"CM Puskas","year":"2017","unstructured":"Puskas CM, Kaida A, Miller CL, Zhang W, Yip B, Pick N, et al. The adherence gap: a longitudinal examination of men\u2019s and women\u2019s antiretroviral therapy adherence in British Columbia, 2000\u20132014. Aids. 2017;31(6):827\u201333.","journal-title":"Aids"},{"issue":"1","key":"13533_CR26","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10461-015-1164-1","volume":"20","author":"SM Sweeney","year":"2016","unstructured":"Sweeney SM, Vanable PA. The Association of HIV-Related Stigma to HIV Medication Adherence: A Systematic Review and Synthesis of the Literature. AIDS Behav. 2016;20(1):29\u201350.","journal-title":"AIDS Behav"},{"key":"13533_CR27","unstructured":"Food and Drug Administration (CDER). Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment guidance for industry. Silver Spring (MD): U.S. Department of Health and Human Services. 2015. p.43. https:\/\/www.fda.gov\/media\/86284\/download#:~:text=This%20guidance%20provides%20recommendations%20for%20the%20development%20of,an%20indication%20for%20the%20treatment%20of%20HIV-1%20infection. Accessed May 1, 2025."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-026-13533-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13533-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-026-13533-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T12:11:55Z","timestamp":1782994315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-026-13533-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["13533"],"URL":"https:\/\/doi.org\/10.1186\/s12879-026-13533-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. The initial ethical approval for each study site were obtained prior to the start of the study, and ethical approval for the amendment were obtained before the implementation of the amendment. Both the initial review and amendments were approved by the Ethics Committee of Beijing YouAn Hospital, Capital Medical University (the leading site). The ethics approval number for Protocol V1.0 is No. JYKLZ[2022]132, and the approval number for Protocol V2.0 is No. JYKLZ[2023]053. The names of all ethics committees and their corresponding ethics approval numbers are provided in Supplementary Table\n                      \n                      [See Additional file\n                      \n                      ]. The study involves no personal privacy issues or commercial interests. During the initial ethical review, an application was submitted to the ethics committee of each center for a waiver of informed consent for participants meeting the following condition: study using human biological materials or data containing identifiable personal information, where the relevant participants can no longer be traced. Except for Public Health Clinical Center of Chengdu, the ethics committees of the other 6 study centers approved the above-mentioned waiver of informed consent for eligible potential participants. Among the 358 participants enrolled in this study, informed consent was waived for 8 participants who met the above criteria; the remaining 350 participants all signed the informed consent form. A total of 644 patients who neither signed the informed consent nor satisfied the waiver criteria were excluded from the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"K.P. is an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Y.Li, Y.F., Y.Liu, F.S., X.L. and Q.W. are employees of MSD China, who may own stock and\/or hold stock options in Merck & Co., Inc., Rahway, NJ, USA. Other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1223"}}